Total receipts for the financial year were $2.02m up 139% from $0.85m in for the year 2016. Revenue from continuing operations for the financial year increased 70% to $1.7m up from $1.0m in 2016.
The Group reported a loss of $4.5m for the financial year, down 26% from $6.0m in 2016. Net cash used in operating activities more than halved (down 51%) to $3.0m. Operating expenses have tightened, as the Company focused on streamlining and building its global distribution presence and leveraging key relationships with key retailers.
This solid progress reflects the significant efforts made over the course of the financial year opening distribution channels, principally in the North American and Australian markets. Into this growing base of stores the Company shipped close to 150,000 product units throughout the financial year.
Over the course of the current financial year the Company set several key milestones:
- Increase distribution amongst our existing key accounts in our three core markets
- Increase the overall retail footprint through strategic focus on high value retail/pharmacy networks
- Expand awareness of Mute amongst clinical channels to begin establishing referrals
Pleasingly, the Company has made significant progress in achieving each of these milestones.
To view the full report, please visit:
About Rhinomed Limited
Rhinomed Limited (ASX:RNO) is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. Rhinomed is seeking to radically improve the way you breathe, sleep, maintain your health and take medication. The company is rapidly commercializing its platform and has brought two products to market that are now sold globally. For more information, go to www.rhinomed.global
CEO & Managing Director
Link: Preliminary Final Report
Rhinomed Limited (ASX:RNO) and US Based Columbia Care LLC to Develop Nasally Delivered Dose Controlled Cannabis Based Medicines